Blog
RSS FeedPosted by Michael Wonder on 19 Mar 2019
Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils
18 March 2019 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...
Posted by Michael Wonder on 17 Mar 2019
On the use of list prices in drug pricing research
14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...
Posted by Michael Wonder on 16 Mar 2019
Institute for Clinical and Economic Review publishes revised protocol for assessing unsupported price increases for prescription drugs
15 March 2019 - Through April 19, ICER is accepting public input on which additional price increases should be included ...
Posted by Michael Wonder on 14 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on siponimod for treating secondary progressive multiple sclerosis
14 March 2019 - Public comment period now open until 10 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 13 Mar 2019
Drug price watchdog ICER dives into Trump fueled pharma rebate debate
13 March 2019 - With public and political winds blowing in the same direction, significant reform of the complicated U.S. ...
Posted by Michael Wonder on 22 Feb 2019
ICER to publish upcoming assessment on additive cardiovascular disease therapies
22 February 2019 - Report will be subject of Midwest CEPAC meeting in September; open input now being accepted until ...
Posted by Michael Wonder on 15 Feb 2019
ICER publishes final new evidence update for alirocumab, a PCSK9 inhibitor for treating high cholesterol
15 February 2019 - Based on new analyses of published results of the ODYSSEY Outcomes trial, alirocumab would meet cost-effectiveness thresholds ...
Posted by Michael Wonder on 23 Jan 2019
ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures
23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...
Posted by Michael Wonder on 21 Jan 2019
New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions
18 January 2019 - A new whitepaper authored by Bruce Pyenson and colleagues from Milliman explains why ICER potential budget ...
Posted by Michael Wonder on 11 Jan 2019
ICER posts draft scoping document for the assessment of treatments for Duchenne muscular dystrophy
11 January 2019 - Document open to public comment until 1 February 2019. ...
Posted by Michael Wonder on 20 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for biologic treatments for uncontrolled asthma
20 December 2018 - Expert roundtable suggests that lower prices, needed to align pricing fairly with the added value for patients, ...
Posted by Michael Wonder on 03 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for extended-release treatments for opioid use disorder
3 December 2018 - CAM2038 could reach fair value-based price if launched with annual price less than $5,300. ...
Posted by Michael Wonder on 29 Nov 2018
Amgen cuts Repatha’s price by 60 percent. Will value-based pricing support value-based patient access?
28 November 2018 - Recently, Amgen announced a 60% reduction in the list price of its PCSK9 drug Repatha for patients ...
Posted by Michael Wonder on 29 Nov 2018
ICER Appoints Athelia "Tia" Tilson as Vice President of Development
29 November 2018 - ICER has appointed Athelia “Tia” Tilson as the organization’s first Vice President of Development. ...
Posted by Michael Wonder on 21 Nov 2018
ICER posts draft scoping document for the assessment of treatments for peanut allergy
20 November 2018 - Document open to public comment until 12 December 2018. ...